Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools (NASDAQ: LAB) has announced its management team's participation in two major investor conferences in November 2024. President and CEO Michael Egholm, PhD, will deliver corporate presentations at the UBS Global Healthcare Conference on November 12 at 1:15 p.m. PT and at the Jefferies London Healthcare Conference on November 19 at 8:30 a.m. GMT. The presentations will be webcast live on the company's Investor Relations page, with recordings archived at investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) ha annunciato la partecipazione del suo team di gestione a due importanti conferenze per investitori nel novembre 2024. Il presidente e CEO Michael Egholm, PhD terrà presentazioni aziendali alla UBS Global Healthcare Conference il 12 novembre alle 13:15 PT e alla Jefferies London Healthcare Conference il 19 novembre alle 8:30 GMT. Le presentazioni saranno trasmesse in diretta sulla pagina delle Relazioni con gli Investitori dell'azienda, con registrazioni archiviate su investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) ha anunciado la participación de su equipo de gestión en dos importantes conferencias para inversores en noviembre de 2024. El presidente y CEO Michael Egholm, PhD realizará presentaciones corporativas en la UBS Global Healthcare Conference el 12 de noviembre a la 1:15 p.m. PT y en la Jefferies London Healthcare Conference el 19 de noviembre a las 8:30 a.m. GMT. Las presentaciones se emitirán en vivo en la página de Relaciones con Inversores de la empresa, con grabaciones archivadas en investors.standardbio.com.
스탠다드 바이오툴스 (NASDAQ: LAB)는 2024년 11월 두 개의 주요 투자자 컨퍼런스에 경영진의 참여를 발표했습니다. 회장兼 CEO 마이클 에골름, PhD는 11월 12일 오후 1시 15분 PT에 UBS 글로벌 헬스케어 컨퍼런스에서 기업 발표를 하고, 11월 19일 오전 8시 30분 GMT에 제퍼리스 런던 헬스케어 컨퍼런스에서 발표할 예정입니다. 발표는 회사의 투자자 관계 페이지에서 실시간으로 방송되며, recordings는 investors.standardbio.com에서 아카이브됩니다.
Standard BioTools (NASDAQ: LAB) a annoncé la participation de son équipe de direction à deux grandes conférences pour investisseurs en novembre 2024. Le président et CEO Michael Egholm, PhD fera des présentations d'entreprise lors de la UBS Global Healthcare Conference le 12 novembre à 13h15 PT et lors de la Jefferies London Healthcare Conference le 19 novembre à 8h30 GMT. Les présentations seront diffusées en direct sur la page des Relations avec les Investisseurs de l'entreprise, avec des enregistrements archivés sur investors.standardbio.com.
Standard BioTools (NASDAQ: LAB) hat die Teilnahme seines Management-Teams an zwei wichtigen Investorenkonferenzen im November 2024 angekündigt. Präsident und CEO Michael Egholm, PhD wird am 12. November um 13:15 Uhr PT eine Unternehmenspräsentation auf der UBS Global Healthcare Conference und am 19. November um 8:30 Uhr GMT auf der Jefferies London Healthcare Conference halten. Die Präsentationen werden live auf der Investor Relations-Seite des Unternehmens übertragen, mit aufgezeichneten Versionen, die unter investors.standardbio.com archiviert werden.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November:
- UBS Global Healthcare Conference on November 12th, 2024
President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PT - Jefferies London Healthcare Conference on November 19th – 21st, 2024
President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 19, 2024, at 8:30 a.m. GMT
Available presentations will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq: LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.
Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms.
Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.
Investor Contact
David Holmes
Gilmartin Group LLC
ir@standardbio.com
FAQ
When is Standard BioTools (LAB) presenting at the UBS Global Healthcare Conference 2024?
What investor conferences is Standard BioTools (LAB) attending in November 2024?
Where can I watch Standard BioTools (LAB) investor conference presentations?